FDA 483 - August Reuchlen GmbH - May 02, 2025

An FDA inspection of August Reuchlen GmbH, a manufacturer in Tuttlingen, Germany, identified two significant issues. The firm failed to adequately document corrective and preventive action activities and results. Additionally, the company's supplier control procedures did not clearly define the type and extent of control to be exercised over contractors and consultants.